A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. Reply

Affiliations

¹ Mount Sinai Hospital, New York, NY.
² Rigshospitalet, Copenhagen, Denmark.
³ Inselspital Bern University Hospital, Bern, Switzerland stephan.windecker@insel.ch.

Comment

George D Dangas et al. N Engl J Med. 2020.

. 2020 Jul 9;383(2):e8.

doi: 10.1056/NEJMc2017351.

¹ Mount Sinai Hospital, New York, NY.
² Rigshospitalet, Copenhagen, Denmark.
³ Inselspital Bern University Hospital, Bern, Switzerland stephan.windecker@insel.ch.

No abstract available

Comment on

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
Martin AC, Smadja DM, Karam N. Martin AC, et al. N Engl J Med. 2020 Jul 9;383(2):e8. doi: 10.1056/NEJMc2017351. N Engl J Med. 2020. PMID: 32640141 No abstract available.
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
Yahagi K, Sato Y, Virmani R. Yahagi K, et al. N Engl J Med. 2020 Jul 9;383(2):e8. doi: 10.1056/NEJMc2017351. N Engl J Med. 2020. PMID: 32640142 No abstract available.
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
Stojkovic S, Sulzgruber P, Niessner A. Stojkovic S, et al. N Engl J Med. 2020 Jul 9;383(2):e8. doi: 10.1056/NEJMc2017351. N Engl J Med. 2020. PMID: 32640143 No abstract available.
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
Alghamry A, Murdoch DJ. Alghamry A, et al. N Engl J Med. 2020 Jul 9;383(2):e8. doi: 10.1056/NEJMc2017351. N Engl J Med. 2020. PMID: 32640144 No abstract available.